Could Blue Light Cure Diabetes?

Current research is underway that involves engineering pancreatic beta cells, which are activated by blue light that causes the cells to increase the amount of insulin produced. Diabetes currently affects more than 30 million Americans and is the cause of 4.1 million cases of diabetic retinopathy in the United States . The beta cells in […]

Gene therapy treatment for AMD in clinical trials

Phase 1 clinical trials on a new gene therapy to treat age-related macular degeneration are currently underway in multiple locations around the country. Early results from the trials are offering promising results and researchers hope gene therapy for wet macular degeneration will be available within the next 3 to 5 years. This new therapy would […]

New Drug for Dry Macular Degeneration?

A new drug to treat the “dry” form of macular degeneration is currently undergoing clinical trials. Allegro Ophthalmics has reported encouraging results from the phase 2 study of Risuteganib. The small phase 2 study involved 40 patients and was conducted over a 28 week period with participants receiving 2 injections. Half of the patients received […]

New Drug Approved for Wet Macular Degeneration

Novartis Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved it’s new drug, BeovuĀ®, for the treatment of wet age-related macular degeneration (AMD). BeovuĀ® (brolucizumab) recently completed two late-stage clinical trials, which tested the safety and efficacy of the intravitreal injection. Wet AMD is an eye condition which can lead to a […]

Medication for Dry Macular Degeneration Coming Soon?

While Wet Macular Degeneration has enjoyed the fruits of great research and effective medications, the more common Dry Macular Degeneration has no similar medications for treatment. That might be changing soon. The company, Allegro Ophthalmics, LLC, has developed the molecule, Risuteganib, which the company states is effective against the oxidative stress in the retina that […]

New implant delivers medicine continuously to eye

The current therapy for treating wet macular degeneration involves costly, frequent injections into the eye. Researchers are currently working on a new therapy that involves putting an implant into the eye that would continuously deliver the medication into the eye. Injection therapy only offers temporary help in preserving central vision with wet macular degeneration and […]

Which medication is best for wet macular degeneration?

Johns Hopkins University School of Medicine researchers studied the ocular as well as systemic effects that three anti-VEGF therapies had on patients. Pegatanib, ranibizumab and bevacizumab were all compared to patients who received no anti-VEGF treatments Researchers evaluated specific studies from databases and focused on 16 randomized controlled trials that had a total of 6347 […]

Revolutionary treatment restores vision

A study that involved a revolutionary treatment using stem cells from the eyes of non-living donors is detailed in STEM CELLS Translational Medicine. Researchers hope that this pioneering treatment may hold the key to finding a cure for blindness that is caused by damage to the cornea. Eight patients with condition known as Limbal stem […]

Gene therapy used to treat AMD

A surgeon at the John Radcliffe Hospital in the UK successfully injected a synthetic gene into a patient’s eye in the hope of stopping the progression of age-related macular degeneration. The patient, Janet Osborne, is the first person to receive the gene therapy in the trial that is being conducted at the John Radcliffe Hospital […]

3D-printed replacement cornea a reality

A new company, Precise Bio, will be creating 3D-printed products for human eyes, including corneas. With almost 10 million people suffering from corneal blindness, these artificially manufactured corneas would greatly reduce the supply limitations that go along with transplant waiting lists. Bioprinters utilize layers of cells and biocompatible materials to print form tissue unlike traditional […]